Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRajshekhar ChakrabortySWShikun WangSVSanjay Vara

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows teclistamab and daratumumab improves hematologic complete response in AL amyloidosis, suggesting better outcomes with reduced cytokine release syndrome.

Key Points

  • Trial demonstrates 80% heme-CR rate at 6 months in AL amyloidosis, highlighting significant therapeutic potential.
  • Key metrics include 80% power to detect heme-CR improvement from 55% historical standard therapy level.
  • Single-arm multicenter trial will evaluate safety and efficacy in patients with newly diagnosed AL amyloidosis.
  • Highlights urgent need for therapies that reduce adverse effects like cytokine release syndrome and cardiac issues.

Cite This Study

Chakraborty et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236de91https://doi.org/10.1182/blood-2025-2197
View Full Paper
Ask AI
Bookmark
Share